Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral panobinostat with subcutaneous bortezomib and oral dexamethasone in relapsed or relapsed/refractory multiple myeloma
2015-001564-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panobinostat in multiple myeloma (MM) (3 arms), sponsored by Novartis. Primary endpoints: Overall response rate by IRC (up to 8 cycles) and Overall response rate by IRC. Started Feb 2016; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-001564-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001564-19.